Latest News

Category: Clinical

See all

First Patient Dosed in Phase III ZIRCON-CP Trial of TLX250-CDx for Kidney Cancer Imaging in Chinese Patients

Clinical, News,

Telix and Grand Pharma today announce that a first patient has been dosed in the Phase III ZIRCON-CP trial of TLX250-CDx positron emission tomography (PET) imaging of clear cell renal cell carcinoma (ccRCC). The patient was successfully dosed and imaged at Beijing Cancer Hospital in Beijing,...

Read more

Telix to Spin Off Rhine Pharma™ to Expand Global Access to Radiopharmaceuticals

Clinical, News,

Telix today announces the spin-off of Rhine Pharma, which has the mission of expanding global access to innovative radiopharmaceuticals for cancer imaging and treatment using two generator-produced isotopes, technetium-99m(99mTc) and...

Read more

First Patient Dosed in Phase II ‘CA-NINE’ Trial of TLX250-CDx for Detection of Recurrent Kidney Cancer After Surgery

Clinical, News,

Telix today announces that the first patient has been dosed in a Phase II trial exploring the clinical utility of Telix’s first-in-class investigational PET[1] agent, TLX250-CDx (89Zr-girentuximab) in recurrent clear...

Read more

‘Highly Accurate’: Telix’s Phase III ZIRCON Trial for Kidney Cancer Imaging Published in The Lancet Oncology

Clinical, News,

Telix today announces that primary results from its Phase III ZIRCON trial have been published in The Lancet Oncology, reporting that Telix’s first-in-class investigational PET agent, TLX250-CDx (Zircaix®, 89Zr-girentuximab), is...

Read more

Telix Completes TLX250-CDx (Zircaix®) BLA Submission for Kidney Cancer Imaging 

ASX, Clinical, News,

Telix today announces that it has completed the submission of a Biologics License Application (BLA) to the United States (U.S.) Food and Drug Administration (FDA) for its investigational radiodiagnostic PET...

Read more

Telix Announces Positive rPFS Data from ProstACT SELECT Trial of TLX591 rADC Therapy Candidate in Prostate Cancer

ASX, Clinical, News,

Telix today announces additional positive data from the ProstACT SELECT trial (“SELECT”) of TLX591 (177Lu rosopatamab tetraxetan), a lutetium-labelled rADC therapy for the treatment of adult patients with PSMA-positive metastatic...

Read more

World First Use of Lightpoint’s SENSEI® Drop-In Gamma Probe in Bladder Cancer Surgery Performed in Spain

Clinical, News,

Lightpoint Surgical Limited (Lightpoint), an affiliate of Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces a world-first bladder cancer sentinel lymph node (SLN) procedure with SENSEI®, Telix's miniature...

Read more

First Patient Dosed in Italian Named Patient (Early Access) Program for TLX250-CDx, Telix’s Kidney Cancer Imaging Agent

Clinical, News,

Telix today announces that the first patient has been dosed in its named patient program in Italy for TLX250-CDx (89Zr-DFO-girentuximab, Zircaix®). TLX250-CDx is the Company’s investigational non-invasive carbonic anhydrase IX...

Read more

QDOSE® Platform Partnership for Personalised Dosimetry in Radiopharmaceutical Therapy

Clinical, News,

QDOSE® Platform Partnership for Personalized Dosimetry in Radiopharmaceutical...

Read more

Telix Highlights Presentations at Upcoming ASCO Genitourinary Cancers Symposium (ASCO GU 2024)

Clinical, News,

Telix today announces presentations featuring the Company’s theranostic programs at the upcoming American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU 2024) to be held in San Francisco, CA...

Read more